Mineralys Therapeutics (Nasdaq: MLYS) announced inducement equity awards granted February 9, 2026 to two new non-executive employees under its 2025 Employment Inducement Incentive Award Plan. The Compensation Committee granted options for 33,504 shares and 25,128 restricted stock units.
Options vest over four years with 25% after one year (vesting commencement date February 9, 2026) and then 1/48th monthly thereafter; RSUs vest 25% on each of four anniversaries. Awards were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
Key Figures
Inducement stock options:33,504 sharesInducement RSUs:25,128 sharesOption vesting period:4 years+5 more
8 metrics
Inducement stock options33,504 sharesGranted to two new non-executive employees
Inducement RSUs25,128 sharesGranted to two new non-executive employees
Option vesting period4 yearsInducement stock options vest over four years
Initial option cliff25%Vests on first anniversary of Feb 9, 2026 commencement date
Monthly option vesting1/48thRemaining option shares vest monthly after first anniversary
RSU vesting schedule25% annuallyRSUs vest 25% on each of four anniversaries from Feb 9, 2026
Vesting start dateFebruary 9, 2026Vesting commencement date for options and RSUs
Price vs 52-week range29.78 vs 8.241–47.65Pre-news price between 52-week low and high
Market Reality Check
Price:$27.86Vol:Volume 1,751,929 is 1.54x...
high vol
$27.86Last Close
VolumeVolume 1,751,929 is 1.54x the 20-day average of 1,135,411 shares.high
TechnicalPrice 29.78 is trading above the 200-day MA at 27.59.
Peers on Argus
MLYS fell 4.15% while close biotech peers were mixed: IMVT (-3.14%), SLNO (-1.72...
1 Up
MLYS fell 4.15% while close biotech peers were mixed: IMVT (-3.14%), SLNO (-1.72%), CRNX (-1.36%), and small gains in VKTX (+0.11%) and XENE (+0.23%). Momentum scans only flagged VKTX with a stronger intraday move of 8.259999752044678% up, suggesting today’s MLYS action was more stock-specific than sector-driven.
Presented favorable CKD and hypertension data for lorundrostat at ASN.
Pattern Detected
Positive clinical and earnings updates have generally seen aligned positive price reactions, while prior inducement/administrative news saw minimal impact.
Recent Company History
Over the past few months, Mineralys has highlighted multiple milestones for lorundrostat, including positive Phase 2 and Phase 3 data recognized by JAMA and presentations at ASN Kidney Week, alongside an NDA filing in late 2025. A strong Q3 2025 update with $593.6M in cash and financing of $287.5M coincided with a 17.04% move higher. Prior inducement award announcements showed modest price changes, indicating such HR-related equity grants have not been major trading catalysts compared with clinical or financial news.
Market Pulse Summary
This announcement details routine inducement stock option and restricted stock unit awards under Nas...
Analysis
This announcement details routine inducement stock option and restricted stock unit awards under Nasdaq Rule 5635(c)(4) for new non-executive employees, vesting over four years from February 9, 2026. Historically, similar HR-related items for Mineralys have produced modest price moves compared with major catalysts like clinical data or earnings, which previously moved shares by up to 17.04%. Investors often contextualize such grants alongside recent insider trading activity and ongoing NDA and trial milestones.
Key Terms
chronic kidney disease, ckd, obstructive sleep apnea, osa, +4 more
8 terms
chronic kidney diseasemedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
ckdmedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.
obstructive sleep apneamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)"
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
osamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)"
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
aldosteronemedical
"other diseases driven by dysregulated aldosterone, announced today that on February 9"
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
restricted stock unitfinancial
"inducement restricted stock unit awards covering 25,128 shares of Mineralys"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
stock optionfinancial
"granted inducement stock option awards covering 33,504 shares and inducement"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
nasdaq listing rule 5635(c)(4)regulatory
"employees, in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
AI-generated analysis. Not financial advice.
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of Mineralys common stock to two new non-executive employees.
The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The options will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of each award’s vesting commencement date, February 9, 2026, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The restricted stock units will vest over a four-year period, with 25% of the shares vesting on each of the four anniversaries of each award’s vesting commencement date, February 9, 2026. The awards were granted as an inducement material to the new non-executive employees entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
What inducement awards did Mineralys Therapeutics (MLYS) grant on February 9, 2026?
Mineralys granted inducement options for 33,504 shares and 25,128 restricted stock units on February 9, 2026. According to the company, the awards were made to two new non-executive employees under its 2025 Inducement Incentive Award Plan.
How do the Mineralys (MLYS) stock options vest from the February 9, 2026 grant?
The options vest over four years with 25% vesting on the first anniversary and then 1/48th monthly thereafter. According to the company, vesting is subject to continued service and uses February 9, 2026 as the commencement date.
What is the vesting schedule for the Mineralys (MLYS) restricted stock units granted February 9, 2026?
The restricted stock units vest over four years with 25% vesting on each anniversary of the February 9, 2026 commencement date. According to the company, vesting is tied to continued employment over the four-year period.
Why did Mineralys Therapeutics (MLYS) grant these inducement awards under Nasdaq rules?
The awards were granted as inducements in reliance on Nasdaq Listing Rule 5635(c)(4) to recruit new employees. According to the company, the grants are material inducements tied to the new hires entering employment.
How many employees received inducement awards from Mineralys (MLYS) in the February 9, 2026 grant?
Two new non-executive employees received the inducement awards granted February 9, 2026. According to the company, the Compensation Committee approved the option and RSU grants under the 2025 inducement plan.
